- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Global Cancer Cases to Grow by 30 Per Cent
2 September 2009
The number of new cancer cases globally will grow by 30% over the next decade, according to a new report from the Economist Intelligence Unit (EIU). By 2020, the number of cases will reach nearly 17 million, an increase of four million on today’s figures. An aging population and the growing prevalence of the disease in the emerging territories are two of the main drivers for the predicted rise. Cancer is already the world’s second biggest killer, claiming more people every year than HIV/AIDS, malaria and tuberculosis combined.
EIU estimates that, with regard to cancer, the price of medical and non-medical costs and lost productivity will total US$286bn in 2009 (an estimation it describes as “conservative”); despite this, only $19bn will be spent on cancer research. The report speculates how much it would cost to achieve a “global funding expenditure standard”, based on achieving per-case spending around the world . It is estimated that achieving this standard, based on 2009 new cancer cases, would require an additional US$217bn.
Commissioned by LIVESTRONG, an initiative of the Lance Armstrong Foundation (LAF), the report, Breakaway: The global burden of cancer - challenges and opportunities, is available free of charge at www.eiu.com/LAF
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
